Sarepta Therapeutics, Inc.
SRPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,899 | $1,676 | $6,214 | $11,707 |
| - Cash | $613 | $511 | $241 | $1,103 |
| + Debt | $1,250 | $1,354 | $1,344 | $1,343 |
| Enterprise Value | $2,536 | $2,519 | $7,317 | $11,947 |
| Revenue | $399 | $611 | $745 | $658 |
| % Growth | -34.6% | -18% | 13.1% | – |
| Gross Profit | $236 | $459 | $607 | $526 |
| % Margin | 59.2% | 75% | 81.5% | 79.9% |
| EBITDA | -$182 | $170 | -$369 | $187 |
| % Margin | -45.5% | 27.8% | -49.5% | 28.4% |
| Net Income | -$180 | $197 | -$448 | $159 |
| % Margin | -45.1% | 32.2% | -60.1% | 24.2% |
| EPS Diluted | -1.795 | 1.89 | -4.6 | 1.5 |
| % Growth | -195% | 141.1% | -406.7% | – |
| Operating Cash Flow | $0 | $261 | -$583 | $92 |
| Capital Expenditures | $0 | -$30 | -$46 | -$38 |
| Free Cash Flow | $0 | $232 | -$629 | $54 |